Skip to main content

Table 2 Summary of treatment-related adverse events (TRAE) in all grades of severity

From: Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors

N (%) Selinexor 60 mg QW/BIW  +  carboplatin 6 AUC Q3W (N  = 6) Selinexor 60 mg QW/BIW  +  doxorubicin 60 mg/m2  +  cyclophosphamide 600 mg/m2 Q3W (N  = 4) Selinexor 40 mg QW  +  FOLFIRIa (N  = 3) Selinexor 60 mg QW  +  irinotecan 125 mg/m2 D1 and 8 Q3W (N  = 3) Selinexor 40 mg QW  +  XELOXb (N  = 3) All patients (N  = 19)
All grades Grade 3/4 All grades Grade 3/4 All grades Grade 3/4 All grades Grade 3/4 All grades Grade 3/4 All grades Grade 3/4
Anemia 5 (83) 2 (33) 2 (50) 0 1 (33) 0 1 (33) 0 1 (33) 1 (33) 10 (53) 3 (16)
Leukopenia 4 (75) 1 (17) 3 (75) 3 (75) 3 (100) 0 1 (33) 0 2 (67) 1 (33) 13 (68) 5 (26)
Neutropenia 4 (75) 2 (33) 3 (75) 3 (75) 2 (67) 1 (33) 2 (67) 1 (33) 1 (33) 1 (33) 12 (63) 8 (42)
Thrombocytopenia 6 (100) 3 (50) 3 (75) 0 2 (67) 0 2 (67) 0 3 (100) 0 16 (84) 3 (16)
Constipation 0 0 0 0 0 0 0 0 0 0 0 0
Diarrhea 2 (33) 0 0 0 0 0 1 (33) 0 1 (33) 1 (33) 4 (21) 1 (5)
Nausea 4 (75) 0 4 (100) 0 1 (33) 0 1 (33) 0 3 (100) 0 13 (68) 0
Vomiting 4 (75) 0 3 (75) 0 0 0 1 (33) 0 2 (67) 0 10 (53) 0
Elevated AST/ALT 0 0 0 0 1 (33) 0 1 (33) 0 0 0 2 (11) 0
Mucositis 0 0 0 0 0 0 0 0 0 0 0 0
Fatigue 4 (75) 0 2 (50) 0 1 (33) 0 3 (100) 1 (33) 1 (33) 0 11 (58) 1 (5)
Anorexia 1 (17) 0 0 0 0 0 1 (33) 0 2 (67) 0 4 (21) 0
Hyponatremia 3 (50) 2 (33) 0 0 1 (33) 1 (33) 1 (33) 0 1 (33) 1 (33) 6 (32) 4 (21)
Hypomagnesemia 1 (17) 0 0 0 0 0 0 0 1 (33) 0 2 (11) 0
Hypoalbuminemia 0 0 0 0 0 0 0 0 0 0 0 0
Dyspnea 0 0 0 0 0 0 0 0 1 (33) 0 1 (5) 0
Cough 0 0 0 0 0 0 0 0 0 0 0 0
Elevated CPK 1 (17) 0 0 0 0 0 0 0 0 0 1 (5) 0
Infection or infestation 0 0 0 0 0 0 0 0 0 0 0 0
Elevated lipase 1 (17) 1 (17) 0 0 0 0 0 0 0 0 1 (5) 1 (5)
  1. aFOLFIRI—irinotecan of 180 mg/m2, 5-FU continuous infusion of 2400 mg/m2, 5-FU bolus of 400 mg/m2, and leucovorin of 400 mg/m2 on days 1, and 15
  2. bXELOX—capecitabine was dosed at 900 mg/m2 orally (PO) divided into 2 doses on days 1–14, along with oxaliplatin of 130 mg/m2 IV Q3W
  3. QW once weekly; BIW twice weekly; AUC area under curve; mg/m2 milligrams per square meter; D1 and 8 on days 1, and 8 of each cycle; Q3W every 3 weeks; ALT alanine aminotransferase; AST aspartate aminotransferase; CPK creatine phosphokinase; FOLFIRI irinotecan with fluorouracil and folinic acid; 5-FU 5-fluorouracil; XELOX capecitabine and oxaliplatin
Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us